IN-LICENSED TECHNOLOGY - Polytherapeutics (Details) - Polytherapeutics - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Mar. 24, 2018 |
Dec. 31, 2022 |
Dec. 31, 2021 |
|
| IN-LICENSED TECHNOLOGY | |||
| Purchase price agreement | $ 40,833 | ||
| Royalty payment period | 10 years | ||
| Percentage of royalty payments of net revenue | 4.00% | ||
| Royalty payments with generic product introduced, as a percent of net revenue | 2.00% | 2.00% | |
| Royalty payments with two or more generic product introduced, as a percent of net revenue | 0.00% | 0.00% | |
| Royalty payments, as a percent of net revenue | 4.00% | ||
| Royalty payments with one generic product introduced, as a percent of net revenue | 2.00% | 4.00% | |